| Autor: |
Verwijmeren D; Reinier van Arkel groep, 's-Hertogenbosch.; Contact: D. Verwijmeren (d.verwijmeren@reiniervanarkel.nl)., Jessurun NT; Bijwerkingencentrum Lareb, 's-Hertogenbosch., Hermens WAJJ; Jeroen Bosch Ziekenhuis, Ziekenhuisapotheek, 's-Hertogenbosch., Butterhoff-Terlingen MH; Tergooi, locatie Hilversum, Klinische Farmacie., Grootens KP; Reinier van Arkel groep, 's-Hertogenbosch. |
| Jazyk: |
Dutch; Flemish |
| Zdroj: |
Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2019 Feb 07; Vol. 163. Date of Electronic Publication: 2019 Feb 07. |
| Abstrakt: |
Serotonin syndrome is a medication-induced clinical syndrome, caused by an increased concentration of serotonin in the central and peripheral nervous system. An excess of serotonin can be caused by the use of one or more serotinergic substances on the one hand, or by decreased clearance of these substances on the other hand We carried out a systematic literature search to make an estimation of substances and patient-related factors that might be associated with an increased risk of serotonin syndrome. We also carried out a search for all reports of serotonin syndrome in the Lareb (Netherlands pharmacovigilance centre) database. Patient-centred medication monitoring is not yet possible because there is an almost complete lack of clinical predictors. For the time being, all that treatment providers can do to help recognise serototin syndrome on time is to be extra alert in patients belonging to risk groups (the elderly, or patients with renal or hepatic insufficiency. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
